Impact of reduced margin pelvic radiotherapy on gastrointestinal toxicity and outcome in gynecological cancer

Lee, Jie; Lin, Jhen-Bin; Weng, Chia-Sui; Chen, Sue-Jar; Chen, Tze-Chien; Chen, Yu-Jen

doi:10.1016/j.ctro.2023.100671

Cited by 1 publication

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment of GCs depends on various factors including the type and stage of cancer [ 18 ], overall health of the patient, and the patient’s preferences [ 19 ]. Treatment options may include surgery to remove the cancerous tissue (laparoscopy, hysterectomy, oophorectomy) [ 20 ], radiation therapy using high-energy radiation beams to destroy cancer cells (externally or internally) [ 21 ], chemotherapy to kill cancer cells (orally or intravenously) in combination with surgery or radiation therapy [ 22 ], targeted drugs [ 23 ], and immunotherapy [ 24 ]. Over the years, treatment strategies for GCs have become more personalized and targeted [ 25 ].…”

Section: Introductionmentioning

confidence: 99%

The emerging roles of long non-coding RNA (lncRNA) H19 in gynecologic cancers

Ghasemian,

Zehtabi,

Dari

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Long non-coding RNA (lncRNA) H19 has gained significant recognition as a pivotal contributor to the initiation and advancement of gynecologic cancers, encompassing ovarian, endometrial, cervical, and breast cancers. H19 exhibits a complex array of mechanisms, demonstrating dualistic effects on tumorigenesis as it can function as both an oncogene and a tumor suppressor, contingent upon the specific context and type of cancer being investigated. In ovarian cancer, H19 promotes tumor growth, metastasis, and chemoresistance through modulation of key signaling pathways and interaction with microRNAs. Conversely, in endometrial cancer, H19 acts as a tumor suppressor by inhibiting proliferation, inducing apoptosis, and regulating epithelial-mesenchymal transition. Additionally, H19 has been implicated in cervical and breast cancers, where it influences cell proliferation, invasion, and immune evasion. Moreover, H19 has potential as a diagnostic and prognostic biomarker for gynecologic cancers, with its expression levels correlating with clinical parameters and patient outcomes. Understanding the functional roles of H19 in gynecologic cancers is crucial for the development of targeted therapeutic strategies and personalized treatment approaches. Further investigation into the intricate molecular mechanisms underlying H19’s involvement in gynecologic malignancies is warranted to fully unravel its therapeutic potential and clinical implications. This review aims to elucidate the functional roles of H19 in various gynecologic malignancies.

show abstract